GlassScriptPhysician profile
Kathryn Eby Beckermann
NPI 1023375391
$84,225.12
in general payments reported to CMS, 2019-2025
17 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $2,444 · 2021: $4,133 · 2022: $5,852 · 2023: $11K · 2024: $19K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $52K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,250 · Travel and Lodging: $5,980 · Food and Beverage: $4,518 · Honoraria: $1,980 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $51,587.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,250.00 |
| Travel and Lodging | $5,980.29 |
| Food and Beverage | $4,517.64 |
| Honoraria | $1,980.00 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $25,838.68 | 2019-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $17,772.19 | 2020-2025 | Welireg, Keytruda, Reblozyl |
| Novartis Pharmaceuticals Corporation | $13,139.92 | 2025 | |
| Eisai INC. | $4,793.99 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,713.36 | 2021-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $4,406.59 | 2025 | Truqap, Lynparza |
| Novartis Pharma Ag | $4,200.00 | 2025 | Pluvicto |
| Janssen Biotech, INC. | $2,257.30 | 2025 | Erleada |
| Aveo Pharmaceuticals, INC. | $2,107.11 | 2022-2025 | Fotivda |
| Genzyme Corporation | $1,734.00 | 2022 | |
| Pfizer INC. | $1,727.10 | 2020-2025 | |
| Coherus Oncology, INC. | $900.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $424.71 | 2024-2025 | Erleada, Akeega |
| Stemline Therapeutics INC. | $119.16 | 2025 | Orserdu |
| Genentech USA, INC. | $68.00 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $23.01 | 2025 | Trodelvy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Beckermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.